Clinical Mass Spectrometry Market, by Product Type (Gas chromatography–mass spectrometry (GC-MS) instrument , Liquid chromatography–mass spectrometry (LC- MS) instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass spectrometry, and

Clinical Mass Spectrometry Market, by Product Type (Gas chromatography–mass spectrometry (GC-MS) instrument , Liquid chromatography–mass spectrometry (LC- MS) instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass spectrometry, and Ion mobility spectrometry-mass spectrometry), by Application (Clinical Testing, Proteomics, and Drug discovery), by End User (Research Laboratories, Diagnostic Laboratories, and Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Clinical mass spectrometry plays a vital role in the drug discovery pipeline for development of personalized medicines. It is further used in live imaging of biological tissue samples for detection of biomarkers. Cost reduction and improved assay quality are the key factors driving the adoption of mass spectrometry technique. According to the American Association for Clinical Chemistry (AACC), the greater specificity of liquid chromatography–mass spectrometry (LC-MS) enables the measuring of testosterone in the patients with low endogenous concentrations. This technique is more reliable than traditional immunoassays, especially in women and children. This has led to an early adoption of the most recent generation of instruments using an established technology in the laboratories.
Clinical diagnostic mass spectrometers have the potential to analyze limited range of samples such as biomarkers, proteins or drug molecules at once, and in
Some cases with low concentrations. Thus, these devices are a valuable tool in diagnostics and laboratory settings. Furthermore, it allows researchers to determine pharmacokinetic profiles of drugs that are administered in micro doses. The technology shift from traditional systems to high-resolution technologies such as Quadrupole-time of flight (Q-TOF) mass spectrometry and the demand for this spectrometry technique type is expected to grow rapidly owing to advantages such as accuracy, improved resolution, and sensitivity for clinical diagnostic applications.
Market Dynamics
Technological advancements and product launches by key players are expected to drive growth of the clinical mass spectrometry market. Advancements in technology include miniaturization of mass spectrometry instruments and increasing automation within spectrometric units to reduce human efforts and improve efficiency of the instrument. For instance, a fully automated analyzer launched by Thermo Fisher, in June 2017 that can be customized for compatibility with laboratory information systems.
Key features of the study:
This report provides in-depth analysis of the global clinical mass spectrometry market size (US$ Mn), and compound annual growth rate (CAGR (%)) over the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global clinical mass spectrometry market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Bruker Corporation Kore Technology Limited, Bergman Messgerate Entwicklung KG, Mass Spectrometry Instruments (MSI), Thermo Fisher Scientific Inc., Agilent Technologies, and Danaher Corporations
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, government initiatives, market expansion, and marketing tactics
The global clinical mass spectrometry report caters to various stakeholders in this industry which include investors, product manufacturers, distributors, and suppliers of clinical mass spectrometry, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
Global Clinical Mass Spectrometry Market, By Product Type:
Gas chromatography-mass spectrometry (GC-MS) instrument
Liquid chromatography-mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
Global Clinical Mass Spectrometry Market, By Application:
Clinical Testing
Proteomics
Drug discovery
Global Clinical Mass Spectrometry Market, By End User:
Research Laboratories
Diagnostic Laboratories
Hospitals
Global Clinical Mass Spectrometry Market, By Region:
North America
By Country:
U.S.
Canada
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type
Gas chromatography–mass spectrometry (GC-MS) instrument
Liquid chromatography–mass spectrometry (LC-MS) instrument
Maldi TOF mass spectrometer
Capillary electrophoresis-mass spectrometry
Ion mobility spectrometry-mass spectrometry
By Application
Clinical Testing
Proteomics
Drug discovery
By End User
Research Laboratories
Diagnostic Laboratories
Hospitals
Company Profiles
Bruker Corporation*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Kore Technologies
Bergman Messgerate Entwicklung KG
Mass Spectrometry Instruments (MSI)
RGB Photonics
ABLE Biosciences
Thermo Fisher Scientific Inc.
Danaher Corporation
Agilent Technologies
PerkinElmer Inc.
Shimadzu Corporation
“*” marked represents similar segmentation in other categories in the respective section.